UKPDS Paper 35 Slides © University of Oxford Diabetes Trials Unit

Slides:

Advertisements

Similar presentations

UKPDS Paper 80 Slides © University of Oxford Diabetes Trials Unit

Advertisements

What to do when basal bolus therapy fails in Type 2 Diabetes [insert name] UKHMG00596a February 2012 Prescribing information can be found on the last slide.

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.

Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Randomisation Avoid ACE inhibitors/ beta-blockers (n = 390) Tight BP control (n =

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

BLOOD PRESSURE LOWERING. UKPDS design Aim To determine whether intensified blood glucose control, with either sulphonylurea or insulin, reduces the risk.

UKPDS Paper 36 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.

UKPDS Paper 81 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

The concept of Diabetes & CV risk: A lifetime risk challenge

Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.

Achieving Diabetes Targets Where are we, and how can we do better? Robert E. Ratner, MD MedStar Research Institute Georgetown University Medical School.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.

ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.

Blood glucose: is lower better for diabetic patients?

These slides were sponsored by Janssen and developed in conjunction with the BRS CKD Strategy Group, following an advisory board that was organised by.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Journal Club 亀田メディカルセンター糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田昌文 Matsuda, Masafumi 2008 年９月 25 日 8:20-8:50 B 棟８階カンファレンス室.

Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Support Diabetes Self-Care On A National Basis Dr. Sheldon Silver Credit Valley Hospital, June 20, 2007.

FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.

Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.

Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.

Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

Glycemic Control: When the Lower is Not the “Better”?

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Prevalence (%) estimates of diabetes (20-79 years) 2010.

Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.

Diabetes type 2 Landmark Outcomes Trials

Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study Dr Jack R W Brownrigg,

The SPRINT Research Group

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Volume 352, Issue 9131, Pages (September 1998)

LEADER trial: Primary Outcome

Disclosure Consultations and Honoraria Grant Support

Pravastatin in Elderly Individuals at Risk of Vascular Disease

HbA1c as a Marker of Glycaemic Control in Diabetes Care

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

on behalf of the LEADER Trial Steering Committee and Investigators

366 میلیون نفر در جهان مبتلا به دیابت هستند.

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Introduction The American Journal of Medicine

The Hypertension in the Very Elderly Trial (HYVET)

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials Sanjay Rajagopalan Journal of Indian College.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Pharmacotherapy for Diabetic Coronary Disease:

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

The Clock is ticking for the world’s leaders

Figure 1 Relationships between magnitude of antithrombotic benefit vs

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus James H. O'Keefe, MD, Mohammad Abuannadi,

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.

Relationship between updated systolic blood pressure (SBP), right, and updated HbA1c, left, and the incidence of microvascular complications (closed symbols)

Presentation transcript:

UKPDS Paper 35 Slides © University of Oxford Diabetes Trials Unit UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study. British Medical Journal 2000; 321: 405-412 UKPDS slides are copyright and remain the property of the University of Oxford Diabetes Trials Unit UKPDS slides are made freely available to non-profit organisations on the understanding that the contents are not altered in any way, other than for translation into other languages Commercial organisations wishing to use UKPDS slides should contact the UKPDS Administrator (ukpds@dtu.ox.ac.uk)

Any Diabetes Related Endpoint . 5 1 6 7 8 9 21% decrease per 1% decrement in HbA1c p<0.0001 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Diabetes Related Deaths 21% decrease per 1% decrement in HbA1c p<0.0001 . 5 1 6 7 8 9 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

All Cause Mortality p<0.0001 Hazard ratio 14% decrease per 1% decrement in HbA1c p<0.0001 . 5 1 6 7 8 9 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Fatal and Non-Fatal Myocardial Infarction 14% decrease per 1% decrement in HbA1c p<0.0001 . 5 1 6 7 8 9 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Fatal and Non-Fatal Stroke . 5 1 6 7 8 9 12% decrease per 1% decrement in HbA1c p=0.035 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Microvascular Endpoints . 5 1 6 7 8 9 37% decrease per 1% decrement in HbA1c p<0.0001 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Cataract Extraction p<0.0001 Hazard ratio . 5 1 6 7 8 9 19% decrease per 1% decrement in HbA1c p<0.0001 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Amputation or Death from Peripheral Vascular Disease . 1 2 5 6 7 8 9 43% decrease per 1% decrement in HbA1c p<0.0001 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Heart Failure p=0.016 Hazard ratio . 5 1 6 7 8 9 16% decrease per 1% decrement in HbA1c p=0.016 Updated mean HbA1c Hazard ratio UKPDS 35. BMJ 2000; 321: 405-12

Myocardial Infarction and Microvascular Disease Updated mean HbA1c (%) Incidence per 1000 patient-years UKPDS 35. BMJ 2000; 321: 405-12

UKPDS 35 Summary There is a direct relationship between the risk of complications of diabetes and glycaemia over time No threshold of glycaemia was observed for a substantive change in risk for any of the clinical outcomes examined The lower the glycaemia the lower the risk for complications The rate of increase of risk for microvascular disease with hyperglycaemia is greater than that for macrovascular disease